AK002

Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023
Antibody, Investment, AK002, Atopic dermatitis, Research, CSU, Patient, Lirentelimab, SAN, Allergy, Pharmaceutical industry, Video game

SAN CARLOS, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • SAN CARLOS, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2023.
  • Allakos reported a net loss of $45.6 million in the third quarter of 2023 compared to $30.8 million in the third quarter of 2022.
  • Net loss per basic and diluted share was $0.52 for the third quarter of 2023 compared to $0.53 in the third quarter of 2022.
  • Allakos ended the third quarter of 2023 with $193.9 million in cash, cash equivalents and investments resulting in a net decrease in cash, cash equivalents and investments of $27.2 million during the third quarter of 2023.

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Monday, March 6, 2023
ENIGMA, SAN, AK002, Research, Antibody, Patient, CSU, Investment, Atopic dermatitis, Depreciation, Lirentelimab, Allergy, Pharmaceutical industry, Video game

Research and development expenses were $35.4 million in the fourth quarter of 2022 compared to $72.9 million in the fourth quarter of 2021.

Key Points: 
  • Research and development expenses were $35.4 million in the fourth quarter of 2022 compared to $72.9 million in the fourth quarter of 2021.
  • Fourth quarter of 2022 research and development expenses decreased significantly compared to the prior year fourth quarter primarily as a result of cost cutting efforts implemented during the first quarter of 2022.
  • General and administrative expenses were $10.8 million in the fourth quarter of 2022 compared to $23.2 million in the fourth quarter of 2021.
  • Allakos reported a net loss of $43.0 million in the fourth quarter of 2022 compared to $94.4 million in the fourth quarter of 2021.

Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology

Retrieved on: 
Tuesday, November 29, 2022
EOE, Skin, SAN, KIT, Nature Communications, Allergy, Myelocyte, Macrophage, Antibody, Lirentelimab, Food, Cell, IND, Safety, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, AK002, EOD, Neoplasm, Drug Quality and Security Act, Annual report, CD47, ADCP, Inflammation, Immunoglobulin E, CD24, Gastrointestinal tract, Cancer, B cell, Eosinophilic esophagitis, Therapy, Tams, DC, EG, C5a, MRGPRX2, Atopic dermatitis, Eosinophil, Vaccine, Pharmaceutical industry

SAN CARLOS, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the publication of “Discovery of an agonistic Siglec-6 antibody that inhibits and reduces human mast cells,” in Communications Biology. The publication describes the generation of Siglec-6 agonist monoclonal antibodies optimized for mast cell inhibition and their ability to suppress mast cell activity in pre-clinical models.

Key Points: 
  • Binding of AK006 to Siglec-6 activates the native inhibitory function of the receptor which in turn reduces mast cell activation.
  • In pre-clinical studies, AK006 inhibited multiple modes of mast cell activation, including IgE, IL-33, KIT, C5a, and MRGPRX2, resulting in the broad suppression of inflammation.
  • In addition to mast cell inhibition, AK006 reduced human tissue mast cells via antibody-dependent cellular phagocytosis (ADCP).
  • These documents contain and identify important factors that could cause the actual results for Allakos to differ materially from those contained in Allakos forward-looking statements.

Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting

Retrieved on: 
Thursday, November 10, 2022
EOE, CD52, GLOBE, Lirentelimab, Private Securities Litigation Reform Act, AK002, EOD, Abstract, B cell, Eosinophilic esophagitis, Immunosuppression, Annual general meeting, Food, Nasdaq, EG, Immunotherapy, Macrophage, Neoplasm, Tams, Eosinophil, Securities Act of 1933, DC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, CD47, Atopic dermatitis, SEC, Ligand, Antibody, Annual report, PD-1, Myelocyte, SITC, Securities Exchange Act of 1934, Allergy, Survival, VAP-1, Safety, Inflammation, Company, Cancer, Gastrointestinal tract, Poster, Cell, Skin, Patient, Justice and Security Act 2013, CD24, Society, Vaccine, Medical imaging, Pharmaceutical industry

SAN CARLOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced a poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting. The poster presentation highlights pre-clinical data supporting Siglec-10 as a promising myeloid target for enhancing anti-tumor immunity in solid tumors.

Key Points: 
  • The poster presentation highlights pre-clinical data supporting Siglec-10 as a promising myeloid target for enhancing anti-tumor immunity in solid tumors.
  • Restoring myeloid cell function has the potential to increase anti-tumor immunity by activating both innate and adaptive immune cells.
  • AK007 is a humanized Siglec-10 antagonist antibody designed to block Siglec-10 interaction with all known ligands (CD24, CD52, and VAP-1).
  • These documents contain and identify important factors that could cause the actual results for Allakos to differ materially from those contained in Allakos forward-looking statements.

Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results

Retrieved on: 
Monday, November 7, 2022
Citadel, New Enterprise Associates, Investment, Atopic dermatitis, SEC, Company, Lirentelimab, CSU, Private Securities Litigation Reform Act, Depreciation, NEA, Inflammation, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Securities Act of 1933, Completeness, Gastrointestinal tract, EOE, Antibody, Alta Partners, SAN, Eosinophilic esophagitis, Annual report, GLOBE, AK002, IND, Skin, Omalizumab, Hives, Eosinophil, Clinical trial, Securities Exchange Act of 1934, Allergy, RTW, Research, Safety, EG, Food, Patient, EOD, B cell, Cell, Therapy, Pharmaceutical industry, Vaccine

SAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the Company) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2022.

Key Points: 
  • SAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the Company) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2022.
  • Research and development expenses were $18.4 million in the third quarter of 2022 compared to $43.6 million in the third quarter of 2021.
  • General and administrative expenses were $13.0 million in the third quarter of 2022 compared to $19.1 million in the third quarter of 2021.
  • These documents contain and identify important factors that could cause the actual results for Allakos to differ materially from those contained in Allakos forward-looking statements.

Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock

Retrieved on: 
Monday, September 19, 2022
Citadel, Securities Exchange Act of 1934, Allergy, Sale, LLC, Securities Act of 1933, Jefferies Group, Madison Avenue, Company, Investment, Private Securities Litigation Reform Act, Jefferies, Alta Partners, NEA, Broadridge Financial Solutions, Annual report, Nasdaq, New Enterprise Associates, Telephone, SAN, Form, Inflammation, SEC, Prospectus, Attention, GLOBE, RTW, AK002, Security (finance), Internet service provider

Before deducting the underwriting discounts and commissions and estimated offering expenses, the company expects to receive total gross proceeds of approximately $150 million.

Key Points: 
  • Before deducting the underwriting discounts and commissions and estimated offering expenses, the company expects to receive total gross proceeds of approximately $150 million.
  • The offering is expected to close on or about September 21, 2022, subject to satisfaction of customary closing conditions.
  • Jefferies is acting as the lead book-running manager and Cowen and LifeSci Capital are acting as joint book-running managers for the offering.
  • Such forward-looking statements include, but are not limited to, the ability and timing for the closing of the offering.

Allakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU)

Retrieved on: 
Monday, September 12, 2022
Adult, Hives, Securities Exchange Act of 1934, Headache, Dizziness, EG, Therapy, Inflammation, Allergy, Safety, Gastrointestinal tract, Journal, EOD, Eosinophilic esophagitis, Food, Drug Quality and Security Act, Flushing, CSU, IND, Antibody, Company, Itch, EOE, Private Securities Litigation Reform Act, Securities Act of 1933, Atopic dermatitis, Omalizumab, Patient, Clinical trial, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, UCT, Eosinophil, UAS7, Cell, Annual report, Lirentelimab, Nasdaq, AK002, SAN, Nausea, SEC, Skin, GLOBE, Swelling, Disease, B cell, Pharmaceutical industry

The Phase 2b CSU clinical trial follows positive results from an open-label Phase 2a clinical trial with intravenous lirentelimab in patients with chronic urticaria, including cohorts of patients with omalizumab nave CSU and omalizumab refractory CSU ( link ).

Key Points: 
  • The Phase 2b CSU clinical trial follows positive results from an open-label Phase 2a clinical trial with intravenous lirentelimab in patients with chronic urticaria, including cohorts of patients with omalizumab nave CSU and omalizumab refractory CSU ( link ).
  • The safety results of the trial were generally consistent with previously reported intravenous lirentelimab clinical trials.
  • Full results of the trial were published in The Journal of Allergy and Clinical Immunology.1
    The Phase 2b clinical trial is a 12-week, multicentered, randomized, double-blind, placebo-controlled trial that will enroll approximately 110 adult patients with antihistamine refractory chronic spontaneous urticaria (including patients with prior biologics treatment).
  • Allakos is developing lirentelimab for the treatment of atopic dermatitis, chronic spontaneous urticaria and potentially additional indications.

Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic Duodenitis

Retrieved on: 
Friday, September 9, 2022
TSS, Inflammation, Safety, IND, Stomach, SAN, Dizziness, ITT, Allergy, B cell, Eosinophilia, Headache, Bloating, EOD, Biopsy, Abdominal pain, GLOBE, Duodenum, Patient, Company, Atopic dermatitis, Population, Symptoms of COVID-19, AK002, Nausea, Flushing, Pharmaceutical industry, Medical imaging, Lirentelimab

SAN CARLOS, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today reported data from EoDyssey, a 24-week, Phase 3, randomized, double-blind, placebo-controlled study of lirentelimab in patients with biopsy confirmed eosinophilic duodenitis (EoD). The trial met its histologic co-primary endpoint, but it did not achieve statistical significance on the patient reported symptomatic co-primary endpoint, in both the intent to treat (ITT) population and in a prespecified subpopulation.

Key Points: 
  • Mild to moderate infusion-related reactions (including flushing, feeling of warmth, headache, nausea, and/or dizziness) occurred in 19.6% of lirentelimab-treated patients and 14.9% of placebo-treated patients.
  • Currently Allakos is not planning to conduct additional studies in eosinophilic gastrointestinal diseases, but may do so in the future.
  • Allakos is conducting a Phase 2 randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with moderate-to-severe atopic dermatitis and a Phase 2b randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with chronic spontaneous urticaria.
  • These documents contain and identify important factors that could cause the actual results for Allakos to differ materially from those contained in Allakos forward-looking statements.

Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, August 4, 2022
FDA, Antibody, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Gastrointestinal tract, Drug Quality and Security Act, Risk, EOE, Lirentelimab, EOD, Inflammation, Initiate, GLOBE, Private Securities Litigation Reform Act, Securities Exchange Act of 1934, SEC, Investment, AK002, IND, Eosinophilic esophagitis, Research, Annual report, Allergy, Patient, Eosinophil, Cell, Company, SAN, B cell, Depreciation, Therapy, Skin, Safety, Atopic dermatitis, Securities Act of 1933, Food, EG, Pharmaceutical industry

Research and development expenses were $34.4 million in the second quarter of 2022 compared to $41.0 million in second quarter of 2021.

Key Points: 
  • Research and development expenses were $34.4 million in the second quarter of 2022 compared to $41.0 million in second quarter of 2021.
  • General and administrative expenses were $14.7 million in the second quarter of 2022 compared to $16.2 million in second quarter of 2021.
  • Allakos reported a net loss of $49.1 million in the second quarter of 2022 compared to $57.2 million in the second quarter of 2021.
  • Net loss per basic and diluted share was $0.90 for the second quarter of 2022 compared to $1.07 in the second quarter of 2021.

Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors

Retrieved on: 
Monday, July 25, 2022
Regulation of tobacco by the U.S. Food and Drug Administration, Allergy, Antibody, AK002, AAOS, Stanford University Medical Center, Stanford University, Inflammation, Time, American Academy, Skin, GLOBE, University, American Academy of Orthopaedic Surgeons, State University of New York Upstate Medical University, History, Atopic dermatitis, Food, SAN, SEC, Lirentelimab, B cell, Immunology, Private Securities Litigation Reform Act, Securities Act of 1933, EOE, Securities Exchange Act of 1934, EOD, Safety, Board, Cell, Intuitive Surgical, Dartmouth College, Eosinophilic esophagitis, William H. Harris (orthopaedic surgeon), Company, Gastrointestinal tract, Patient, Orthopedic surgery, Specialty Society Relative Value Scale Update Committee, Professor, Therapy, Annual report, Rochester, EG, Drug Quality and Security Act, Eosinophil, Pharmaceutical industry

We are very pleased to have such an accomplished physician as Dr. Ladd join our board.

Key Points: 
  • We are very pleased to have such an accomplished physician as Dr. Ladd join our board.
  • Dr. Ladd is also a member of the board of directors for Intuitive Surgical, Inc. and the Perry Initiative.
  • Previously, she served as the chair of the American Academy of Orthopaedic Surgeons (AAOS) Board of Specialties Society and is a past member of the AAOS board of directors.
  • These documents contain and identify important factors that could cause the actual results for Allakos to differ materially from those contained in Allakos forward-looking statements.